<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870828</url>
  </required_header>
  <id_info>
    <org_study_id>SilesianMU1</org_study_id>
    <nct_id>NCT03870828</nct_id>
  </id_info>
  <brief_title>Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study</brief_title>
  <official_title>Incidence, Clinical Characteristics and Evaluation of Prognostic and Diagnostic Markers of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 by the Working&#xD;
      Group of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) as&#xD;
      interstitial pneumonia with some clinical and/or serological features suggesting presence of&#xD;
      an underlying autoimmune disorder. However, ofiicial criteria for diagnosis of an autoimmune&#xD;
      disease are not met.&#xD;
&#xD;
      Aims of the study:&#xD;
&#xD;
        1. Determine the incindence of IPAF in comparison with interstitial lung diseases (ILDs)&#xD;
           and classic autoimmune diseases (ADs) in polish pulmonological centers.&#xD;
&#xD;
        2. Clinical, serological, functional and radiological and histopathological characteristics&#xD;
           of IPAF patients.&#xD;
&#xD;
        3. Analysis of diagnostic strategies towards specific IPAF subgroups.&#xD;
&#xD;
        4. Characterictics of potencial diagnostic, predictive and prognostic features of IPAF.&#xD;
&#xD;
        5. Prospective assessment of IPAF patients in the courseof 5 years in order to determine&#xD;
           stability of the diagnosis and potential progression to other diseases, e.g. ADs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following patient groups will be studied:&#xD;
&#xD;
        1. Study group - IPAF.&#xD;
&#xD;
        2. Control groups:&#xD;
&#xD;
             1. Connective tissue disease associated interstitial lung disease (CTD-ILD) patients:&#xD;
                .rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM,&#xD;
                dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjoegren's syndrome - SjS,&#xD;
                mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE,&#xD;
                diagnosed according to diagnostic criteria issued by European League Against&#xD;
                Rheumatism (EULAR) and/or American College of Rheumatology (ACR)&#xD;
&#xD;
             2. Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF,&#xD;
                nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP,&#xD;
                acute interstitial pneumonia - AIP; respiratory bronchiolitis associated&#xD;
                interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP,&#xD;
                lymphocytic interstitial pneumonia - LIP).&#xD;
&#xD;
                Methods Patients will be assessed by a pulmonologist and rheumatologist.&#xD;
                Questionnaires regarding clinical symptoms, concomitant diseases and their&#xD;
                treatment, disease activity will be fulfilled.&#xD;
&#xD;
                The majority of diagnostic tests and procedures are routinely performed during&#xD;
                clinical care.&#xD;
&#xD;
                The study will be divided into 2 phases:&#xD;
&#xD;
                  1. Phase 1 - visit 1&#xD;
&#xD;
                  2. Phase 2 - observation of selected subjects from visit 1 to 5&#xD;
&#xD;
                Phase 1:&#xD;
&#xD;
                30 patients meeting the eligibility criteria, including individuals with a long&#xD;
                medical history and currently undergoing treatment for interstitial lung disease/&#xD;
                autoimmune disorder are going to be recruited to the study in every clinical&#xD;
                center, totaling up to:&#xD;
&#xD;
                  -  210 patients in IPAF group&#xD;
&#xD;
                  -  210 patients in CTD-ILD group&#xD;
&#xD;
                  -  210 patients in IIP group&#xD;
&#xD;
                Phase 2 Only newly diagnosed patients (individuals who have not been previously&#xD;
                diagnosed with interstitial lung disease, and such diagnosis was set during phase 1&#xD;
                of the study) will be recruited to this phase. Due to rare incidence, the&#xD;
                recruitment phase may take up to 36 months.&#xD;
&#xD;
                The total number of patients will be&#xD;
&#xD;
                  -  70 in IPAF group&#xD;
&#xD;
                  -  70 in CTD-ILD group (RA, SSc, PM, DM)&#xD;
&#xD;
                  -  70 in IIP group (35 with IPF and 35 with NSIP, COP and LIP)&#xD;
&#xD;
                Visit 1:&#xD;
&#xD;
                • The following tests and procedures will be performed:&#xD;
&#xD;
                  -  Detailed anamnesis obtained through 'visit 1 questionnaire' [non-routine&#xD;
                     procedure]&#xD;
&#xD;
                  -  Lung function tests (spirometry with reversibility testing, plethysmography,&#xD;
                     diffusion lung capacity for carbon monoxide) [routine procedure]. Absolute&#xD;
                     value and % of the reference value will be assessed.&#xD;
&#xD;
                FEV1 - Forced expiratory volume in 1 second FVC - Forced vital capacity VC - Vital&#xD;
                capacity FEV1/VC, ratio TLC - Total lung capacity, DLCO SB - The carbon monoxide&#xD;
                diffusion capacity (single breath method) ITGV - intrathoracic gas volume RV/TLC -&#xD;
                Residual volume/ Total lung capacity ratio&#xD;
&#xD;
                  -  validated methods of cough assessment [routine procedure]: Chung cough&#xD;
                     questionnaire and Visual analogue scale (VAS).&#xD;
&#xD;
                  -  validated methods of dyspnea assessment [routine procedure]: Likert dyspnea&#xD;
                     questionnaire and modified Borg scale.&#xD;
&#xD;
                Blood testing. In total 30 ml blood will be drawn (15 ml blood into a plain&#xD;
                microtube without anticoagulant and 15ml blood into anticoagulation microtube).&#xD;
                Detailed description below:&#xD;
&#xD;
                NT-proBNP, laboratory tests performed during diagnostic process of rheumatologic&#xD;
                diseases and potential IPAF markers [routine procedure]. 15 ml venous blood will be&#xD;
                drawn and divided into 2 microtubes (10 ml and 5 ml) without anticoagulant 10 ml&#xD;
                microtube will be expedited to a local laboratory in order to measure plasma levels&#xD;
                of NT-proBNP and the following autoantibodies' titer:&#xD;
&#xD;
                  -  rheumatoid factor (RF),&#xD;
&#xD;
                  -  Anti-Citrullinated Protein Antibodies (ACPA; anti-CCP),&#xD;
&#xD;
                  -  Antinuclear Antibodies (ANA) (ANA 1 test performed as screening); in case of&#xD;
                     ANA presence and further staining pattern identification (e.g. homogenous,&#xD;
                     speckled, peripheral, nucleolar, centromere), further tests will be performed&#xD;
                     (ANA 2 and ANA 3):&#xD;
&#xD;
                       -  anti-dsDNA,&#xD;
&#xD;
                       -  anti-Sm,&#xD;
&#xD;
                       -  anti-SS-A (Ro),&#xD;
&#xD;
                       -  anti-SS-B (La),&#xD;
&#xD;
                       -  anti-Scl-70,&#xD;
&#xD;
                       -  anti-RNP,&#xD;
&#xD;
                       -  anti-Jo-1 and anti-PL-7, anti-PL12,&#xD;
&#xD;
                       -  anti-Mi-2,&#xD;
&#xD;
                       -  anti-PM-Scl,&#xD;
&#xD;
                       -  anti-MDA5. From the second 5 ml microtube, after clot has formed, ca&#xD;
                          2,5ml serum will be drawn away with a pipette; serum will be later&#xD;
                          divided into 5 Eppendorf type microtubes (0,5 ml each). These microtubes&#xD;
                          should be labeled according to the following: first letter of the&#xD;
                          patient's name- first letter of the patient's surname/ gender F or M/date&#xD;
                          of birth DD-MM-YY/date of sample collection DD-MM-YY, e.g.&#xD;
                          AL/K/12.05.45/01.02.18. The samples will be stored in -70 °C. The samples&#xD;
                          will be collected by a courier and transported to the clinical center&#xD;
                          responsible for this part of the study. This sample will be used to test&#xD;
                          for potential IPAF markers, e.g. chemokine C-C motif ligand 18 (CXCL18),&#xD;
                          Surfactant Protein A- (SP-A), Surfactant Protein D (SP-D), Krebs von den&#xD;
                          Lungen-6 protein (KL-6) and chitotrisidase 1 (CHIT1) [non-routine&#xD;
                          procedure].&#xD;
&#xD;
                Blood sample collection [procedure not routinely performed during clinical care].&#xD;
                15 ml of whole venous blood will be drawn and then divided into 10 Eppendorf tubes&#xD;
                1, 5 ml each. The tubes will be labeled as described above. The specimens will be&#xD;
                stored in -70 °C. The samples will be transported to the clinical center&#xD;
                responsible for this part of the study.&#xD;
&#xD;
                Optionally, additional tests (testing for proteomic and metabolomic biomarkers)&#xD;
                will be performed in samples of biological material collected beforehand (BALF,&#xD;
                serum, urine [non-routine procedure].&#xD;
&#xD;
                o Bronchofiberoscopy with bronchalveolar lavage (BF + BAL), performing biopsy of&#xD;
                the bronchi mucosa: BF + BAL [routine procedure]: before starting BF, regional&#xD;
                anesthesia and sedation with use of lidocaine and midazolam will be performed,&#xD;
                according to anesthesia protocols applied in respective endoscopy units.&#xD;
                Intravenous cannula will be inserted prior to BF. During endoscopy, the patient&#xD;
                will be monitored according to safety protocols applied in respective endoscopy&#xD;
                units.&#xD;
&#xD;
                Bronchoalveolar lavage will be performed in the bronchus from the middle robe of&#xD;
                right lung or the lingula of left lung (B4, B5). Localization will be chosen based&#xD;
                on HRCT results and will be recorded in patient's medical history. Sterile solution&#xD;
                of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in&#xD;
                portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid&#xD;
                is retrieved.&#xD;
&#xD;
                Bronchoalveolar lavage fluid (BALF) testing. Preparation of microscopic slides,&#xD;
                analysis of the cellular components of the specimen (kind of the most abundant&#xD;
                cells retrieved, the cells' durability) will be performed according to a standard&#xD;
                laboratory procedure (guidelines of the Polish Respiratory Society). Total cell&#xD;
                count along with cells' durability will be measured in a sample taken from the&#xD;
                filtrate or material after the first spin. Cytospin (routinely 10 min of 1200-2000&#xD;
                rpm) will be used to prepare the material. May-Grunewald-Giemsa stain will be used&#xD;
                to prepare the microscopic slides.&#xD;
&#xD;
                BALF samples will be secured and stored in order to test for potential IPAF&#xD;
                markers. 15 ml BALF will be divided into Eppendorf 1,5 ml microtubes and then&#xD;
                stored in - 70 C. Samples will be checked for concentration of S1009A protein,&#xD;
                chemokine (C-C motif) ligand 2 and chitotrisidase 1 (CHIT 1).&#xD;
&#xD;
                Specimens of bronchial mucosa taken during BF [procedure not routinely performed&#xD;
                during clinical care]. 5 mucosa specimens will be taken from the initial segment of&#xD;
                the middle lobe bronchus, placed into Eppendorf microtubes and stored in -80 C.&#xD;
                Specimen will be sent for histopathological assessment.&#xD;
&#xD;
                  -  6 minute walking test - (6MWT) performed according to a protocol applied in&#xD;
                     respective clinical centers [routine procedure]. The following data should be&#xD;
                     recorded:&#xD;
&#xD;
                     • Whether the patient completed the test. If 6MWT was interrupted, the reason&#xD;
                     should be recorded (e.g. dyspnea, high blood pressure, cardiac arrhythmia,&#xD;
                     intermittent claudication, other)&#xD;
&#xD;
                     • Distance in meters&#xD;
&#xD;
                       -  Pulse oximetry measured before and directly after the test&#xD;
&#xD;
                       -  Dyspnea measurement - Borg scale&#xD;
&#xD;
                  -  High resolution computed tomography (HRCT) [routine procedure]. Current&#xD;
                     tomography, performed according to protocol applied in respective clinical&#xD;
                     centers or CT 6 months prior to the study will be eligible. Test results&#xD;
                     (saved on CD) and radiological description will be used. CD will be labeled in&#xD;
                     a way described above. OsiriX Lite software will be used to assess the scans.&#xD;
                     The following densitometric values will be measured: mean lung attenuation&#xD;
                     (MLA), kurtosis, skewness, and standard deviation of lung radiodensity (SD&#xD;
                     I.R). Data analysis will be performed with Statistica software. Data will be&#xD;
                     presented as median and interquartile ranges (IQR). Quantitative data will be&#xD;
                     analyzed with Kruskal-Willis' and Dunn's post hoc tests&#xD;
&#xD;
                  -  Pulse oximetry (SpO2) [routine procedure]. If SpO2 is measured to be &lt; 92% or&#xD;
                     if there are indications for oxygen therapy, arterial blood gas will be&#xD;
                     performed.&#xD;
&#xD;
                  -  Transthoracic echocardiography (TTE) [routine procedure] with detailed right&#xD;
                     heart assessment:&#xD;
&#xD;
                Pulmonary artery diameter Acceleration time (Act) and pulmonary regurgitation&#xD;
                Tricuspid annulus systolic velocity Tricuspid regurgitation velocity. Tricuspid&#xD;
                annular plate systolic excursion, (TAPSE) Basal right ventricle (RV) diameter, mid&#xD;
                RV diameter and base-apex dimension Right ventricle inflow tract dimension Right&#xD;
                ventricle outflow tract dimension Right ventricle diameter measured at the level of&#xD;
                pulmonary valve Right atrial volume Superior vena cava dimension Inferior vena cava&#xD;
                dimension Right ventricular wall thickness (RVWT) o Rheumatology consultation of&#xD;
                every patient in IPAF and autoimmune disorder groups [procedure routinely performed&#xD;
                during clinical care].&#xD;
&#xD;
                Qualification for visit 2-5 - only patients qualified to phase 2 of the study&#xD;
&#xD;
                Visit 2:&#xD;
&#xD;
                • 6 +/- 3 months from visit 1:&#xD;
&#xD;
                  -  Visit 1-5 questionnaire [non-routine procedure]&#xD;
&#xD;
                  -  Lung function tests [routine procedure]&#xD;
&#xD;
                  -  6MWT [routine procedure]&#xD;
&#xD;
                  -  Pulse oximetry [routine procedure]&#xD;
&#xD;
                Visit 3:&#xD;
&#xD;
                • 12 +/- 3 months from visit 1:&#xD;
&#xD;
                  -  Visit 1-5 questionnaire [non-routine procedure]&#xD;
&#xD;
                  -  Lung function tests [routine procedure]&#xD;
&#xD;
                  -  6MWT [routine procedure]&#xD;
&#xD;
                  -  HRCT [routine procedure]&#xD;
&#xD;
                  -  Blood testing (basic laboratory tests [routine procedure], screening for&#xD;
                     autoantibodies and cytokine concentration [non-routine procedure]&#xD;
&#xD;
                  -  BF + BAL [optionally; routine procedure]&#xD;
&#xD;
                  -  Arterialized capillary blood gas [routine procedure]&#xD;
&#xD;
                  -  TTE with detailed right heart assessment [routine procedure]&#xD;
&#xD;
                  -  Rheumatology consultation [routine procedure]&#xD;
&#xD;
                Visit 4:&#xD;
&#xD;
                • 24 +/- 3 months from visit 1:&#xD;
&#xD;
                  -  Visit 1-5 questionnaire [non-routine procedure]&#xD;
&#xD;
                  -  Lung function tests [routine procedure]&#xD;
&#xD;
                  -  6MWT [routine procedure]&#xD;
&#xD;
                  -  HRCT [routine procedure]&#xD;
&#xD;
                  -  Blood testing (basic laboratory tests [routine procedure], screening for&#xD;
                     autoantibodies and cytokine concentration [non-routine procedure]&#xD;
&#xD;
                  -  BF + BAL (optionally; routine procedure]&#xD;
&#xD;
                  -  Arterialized capillary blood gas [routine procedure]&#xD;
&#xD;
                Visit 5&#xD;
&#xD;
                • 60 +/- 3 months from visit 1&#xD;
&#xD;
                o Visit 1-5 questionnaire [non-routine procedure]&#xD;
&#xD;
                o Lung function tests [routine procedure]&#xD;
&#xD;
                o 6MWT [routine procedure]&#xD;
&#xD;
                  -  HRCT [routine procedure]&#xD;
&#xD;
                  -  Blood testing (basic laboratory tests [routine procedure], screening for&#xD;
                     autoantibodies and cytokine concentration [non-routine procedure]&#xD;
&#xD;
                  -  BF + BAL (optionally; routine procedure)&#xD;
&#xD;
                  -  Arterialized capillary blood gas testing [routine procedure]&#xD;
&#xD;
                  -  TTE with detailed right heart assessment [routine procedure]&#xD;
&#xD;
                  -  Rheumatology consultation [routine procedure]&#xD;
&#xD;
                  -  Optionally, in case of clinical and/or radiological progression, worsening of&#xD;
                     lung function tests' results, criobiopsy. may be repeated after obtaining&#xD;
                     informed patient consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of IPAF diagnostic markers</measure>
    <time_frame>10.2019-10.2020</time_frame>
    <description>It is still unclear whether there are diagnostic markers specific for IPAF or whether there is a significant difference in concentration of fibrosis biomarkers in IPAF, CTD-ILD and ILD groups. Both blood and BAL biomarkers will be taken under consideration, they include chemokine C-C motif ligand 18 (CXCL18), Surfactant Protein A- (SP-A), Surfactant Protein D (SP-D), Krebs von den Lungen-6 protein (KL-6) and chitotrisidase 1 (CHIT1).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Interstitial Pneumonia</condition>
  <condition>Interstitial Fibrosis</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Study group IPAF</arm_group_label>
    <description>Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.&#xD;
The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group CTD-ILD</arm_group_label>
    <description>Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group ILD</arm_group_label>
    <description>Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchoalveolar lavage and taking bronchial mucosa samples</intervention_name>
    <description>Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.&#xD;
Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved.</description>
    <arm_group_label>Control group CTD-ILD</arm_group_label>
    <arm_group_label>Control group ILD</arm_group_label>
    <arm_group_label>Study group IPAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>6minute walk test</intervention_name>
    <description>a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation</description>
    <arm_group_label>Control group CTD-ILD</arm_group_label>
    <arm_group_label>Control group ILD</arm_group_label>
    <arm_group_label>Study group IPAF</arm_group_label>
    <other_name>6MWT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial blood gas</intervention_name>
    <description>If SpO2 is measured to be &lt; 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.</description>
    <arm_group_label>Control group CTD-ILD</arm_group_label>
    <arm_group_label>Control group ILD</arm_group_label>
    <arm_group_label>Study group IPAF</arm_group_label>
    <other_name>ABG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood drawing</intervention_name>
    <description>A vein will be punctured in order to take a blood sample for further tests</description>
    <arm_group_label>Control group CTD-ILD</arm_group_label>
    <arm_group_label>Control group ILD</arm_group_label>
    <arm_group_label>Study group IPAF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The following biospecimens will be collected:&#xD;
&#xD;
        -  blood (whole venous blood and serum)&#xD;
&#xD;
        -  bronchoalveolar lavage fluid&#xD;
&#xD;
        -  samples of bronchial mucosa&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be recruited from patients hospitalized in pneumonology wards in&#xD;
        clinical centers participating in the study. They will be divided into 3 subgroups:&#xD;
&#xD;
        Study group - IPAF. 2. Control groups:&#xD;
&#xD;
          1. Connective tissue disease associated interstitial lung disease (CTD-ILD) patients:&#xD;
&#xD;
          2. Idiopathic interstitial pneumonia group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent to participate in the study&#xD;
&#xD;
          -  diagnosis of one of interstitial lung diseases/autoimmune diseases as described below&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  withdrawal od consent&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  lactation&#xD;
&#xD;
          -  infectious disease 4 weeks prior&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szymon Skoczynski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Slaski Uniwersytet Medyczny</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Barczyk, Professor</last_name>
    <phone>+48324796101</phone>
    <email>adagne@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrycja Rzepka-Wrona, MD</last_name>
    <phone>+48324796101</phone>
    <email>patrycja.rzepka2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universita' degli Studi di Messina</name>
      <address>
        <city>Messina</city>
        <state>Province Of Messina</state>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaetano Caramori, Professor</last_name>
      <phone>390906761</phone>
      <email>pneumologia@polime.it</email>
    </contact>
    <investigator>
      <last_name>Gaetano Caramori, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pneumonologii, Onkologii i Alergologii Uniwersytetu Medycznego w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Janusz Milanowski, Professor</last_name>
      <phone>48817244431</phone>
      <email>janusz.milanowski@umlub.pl</email>
    </contact>
    <investigator>
      <last_name>Janusz Milanowski, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Mackiewicz, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>II Katedra Chorob Wewnetrznych Uniwersytetu Jagiellonskiego Collegium Medicum im. prof. A. Szczeklika Szpitala Uniwersyteckiego</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-066</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Krzysztof Sladek, Professor</last_name>
      <phone>48124305147</phone>
      <email>krzysztof.sladek@uj.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Sladek, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Alergologii Gdanskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ewa Jassem, Professor</last_name>
      <phone>48583492625</phone>
      <email>ejassem@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Jassem, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pneumonologii Slaskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Adam Barczyk, Professor</last_name>
      <phone>48324796101</phone>
      <email>adagne@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Adam Barczyk, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrycja Rzepka-Wrona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Szymon Skoczynski, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa Sozanska, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 im. prof. St. Szyszko Sląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Zabrze</city>
        <state>Slask</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Dariusz Ziora, Professor</last_name>
      <phone>48323732235</phone>
      <email>zioradar@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Ziora, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytetu Medycznego im. K. Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-514</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Halina Batura-Gabryel, Professor</last_name>
      <phone>48618417061</phone>
      <email>halinagabryel@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Halina Batura-Gabryel, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Adam Barczyk</investigator_full_name>
    <investigator_title>Professor, Ph.D., M.D.</investigator_title>
  </responsible_party>
  <keyword>IPAF</keyword>
  <keyword>CTD-ILD</keyword>
  <keyword>ILD</keyword>
  <keyword>diagnostic markers</keyword>
  <keyword>progression markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

